Olaparib composition capsules

A technology of composition and capsule, applied in the field of olaparib composition capsule, which can solve the problems of no further prompting, difficulty in quality control, aging, etc.
CN107375232AInactive Publication Date: 2017-11-24HUNAN QIWEI TECH CO LTD
6 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
HUNAN QIWEI TECH CO LTD
Publication Date
2017-11-24
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to the field of pharmaceutical preparations, and specifically discloses an olaparib composition capsule. The olaparib composition capsule of the present invention comprises olaparib, mannitol, dextrin, potassium metaphosphate, polacrilin potassium, and acetylated monoglyceride. The present invention preferably uses olaparib, mannitol, dextrin, potassium metaphosphate, polacrilin potassium, and acetylated monoglyceride as the composition of olaparib capsules, and the mutual synergy improves the stability of olaparib, Fluidity and dissolution rate, reducing water content, is conducive to the safe use and long-term storage of clinical drugs.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of pharmaceutical preparations, in particular to an olaparib composition capsule. Background technique

[0002] Olaparib, chemically known as 4-[3-(4-cyclopropanecarboxy-piperazine-1-carboxy)-4-fluoro-benzyl]-2H-phenazin-1-one, can be used to provide poly- ADP-ribose polymerase (PARP) inhibition. This effect can be used in the treatment of cancers, such as breast or ovarian cancer, which can be particularly effective in the treatment of cancers whose cells are defective in the homologous recombination (HR)-dependent DNA double bond break (DSB) repair pathway, such as BRCA1+ and / or BRCA2+ve cancer.

[0003] 4-[3-(4-Cyclopropanecarboxy-piperazine-1-carboxy)-4-fluoro-benzyl]-2H-phenol is disclosed and exemplified in International Patent Application Publication No. WO2004 / 080976 (compound 168) Oxin-1-ones, which have the following structure:

[0004]

[0005] Olaparib is a drug with low solubility and low bioavail...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More